Clinical Trial Update: A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease [Phase 2]

View source ↗

Summary

Phase 2 study assessing long-term safety of siltuximab in Multicentric Castleman's disease; results from a completed trial have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multicentric Castleman Disease

Drugs mentioned

• Siltuximab (siltuximab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Multicentric Castleman's Disease | Phase 2 | Status: COMPLETED | Results posted: 2018-03-29